Clarify Pharma PLC Clarify Pharma Makes First Capital Investment (8186I)
August 17 2021 - 2:00AM
UK Regulatory
TIDMPSYC
RNS Number : 8186I
Clarify Pharma PLC
17 August 2021
Press Release
17 August 2021
Clarify Pharma PLC
("Clarify Pharma" or the "Company")
First Capital Investment Made
Clarify Pharma (AQSE: PSYC), an investment vehicle specialising
in biotech and life sciences companies seeking to prove the safety
and efficacy of psychedelic-based substances, is pleased to
announce a maiden equity investment of approximately US$700,000
into Beckley Psytech Limited ("Beckley Psytech"), a private company
dedicated to addressing neurological and psychiatric disorders
through the novel application of psychedelic medicines.
The investment is being made as part of a Series B fundraising
by Beckley Psytech, which is incorporated in the UK, and will give
Clarify Pharma a 0.26% interest in the business.
Beckley Psytech is dedicated to helping patients suffering from
neurological and psychiatric disorders by developing a pipeline of
psychedelic compounds into licensed pharmaceutical medicines. Its
development programs will focus on offering innovation and clear
differentiation in the marketplace over existing treatment
options.
Beckley Psytech is supported by an experienced management team
and was founded by long-time psychedelic researcher Lady Amanda
Feilding and its CEO, Cosmo Feilding Mellen. It has a close
strategic partnership with the Beckley Foundation, a renowned
non-profit NGO with a 20-year track record of advancing scientific
research into psychedelic medicine. Its Scientific Advisory Board
includes psychiatric and psychedelic experts such as Dr. Robin
Carhart-Harris from Imperial College London, Prof. Matthew Johnson
from Johns Hopkins University, Frederick Reinholdt from Kings
College London and Prof. Guy Goodwin from the University of
Oxford.
Jonathan Bixby, Executive Chairman of Clarify Pharma, said:
"Beckley Psytech is a pioneer in psychedelic medicine and we look
forward to working with such a reputable company backed by leading
figures in this cutting-edge medical field. This investment
confirms Clarify Pharma's commitment to support the development of
safe alternative therapies to existing mainstream medical
practices. We are delighted to be part of a company that is paving
the way in this new growth frontier."
Cosmo Feilding Mellen, CEO of Beckley Psytech, said: "We are
extremely pleased to welcome Clarify Pharma's investment in Beckley
Psytech. This newly raised capital will enable us to realise our
long-term vision by further advancing our ambitious research
programmes into the development of psychedelics as licensed
pharmaceutical treatments for neurological and psychiatric
disorders."
For further information please contact:
Clarify Pharma
Jon Bixby via Tancredi +44 207 887 7633
Executive Chairman
------------------------------
First Sentinel
------------------------------
Corporate Adviser
Brian Stockbridge +44 7876 888 011
------------------------------
Tennyson Securities
------------------------------
Corporate Broker
Peter Krens +44 207 186 9030
------------------------------
Tancredi Intelligent Communication
------------------------------
Media Relations
Catrina Daly
Emma Hodges +44 7727 153 868
Salamander Davoudi +44 7861 995 628
clarifypharma@tancredigroup.com +44 7957 549 906
------------------------------
About Clarify Pharma
Clarify Pharma is an investment vehicle focusing on investing in
biotech and life sciences companies seeking to prove the safety and
efficacy of psychedelic-based substances. The Company looks to
identify investment opportunities in the life sciences sector
within the UK, Canada and other growing markets, with the objective
of generating long-term capital growth and building investments in
an R&D pipeline of companies which are discovering, developing,
or deploying safe and evidence-based psychedelic inspired medicines
and experiential therapies that alleviate mental health problems
and enhance wellbeing.
Clarify Pharma is working to assemble a portfolio of companies
that focus on the development of psychedelic inspired medicines and
experiential therapies for human clinical trials under the
supervision and strict adherence to the guidelines of the United
Kingdom's MHRA, Canada's Health Canada as well as similar
regulatory authorities in other jurisdictions where Clarify or its
investee companies operate.
The Company's Directors have an established track record,
experience and networks in the psychedelic, cannabinoid and media
industries, to drive value creation.
https://www.clarifypharma.com/
About Beckley Psytech
Beckley Psytech is a clinical stage privately held company
dedicated to helping patients suffering from neurological and
psychiatric disorders by developing a broad pipeline of psychedelic
compounds in rare and more common diseases. Beckley Psytech's
vision is for clinically validated psychedelic medicines to be
integrated into modern medical practice in order to help patients
with high unmet medical need around the world, suffering from
Short-lasting unilateral neuralgiform headache attacks, treatment
resistant depression and other profoundly debilitating conditions.
Beckley Psytech was founded in 2019 leveraging some of the
expertise developed over more than 20 years by the Beckley
Foundation, a world leader in psychedelic medicine research, and is
based out of Oxford, United Kingdom.
https://www.beckleypsytech.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXSFWEFMEFSESA
(END) Dow Jones Newswires
August 17, 2021 02:00 ET (06:00 GMT)
Clarify Pharma (AQSE:PSYC)
Historical Stock Chart
From May 2024 to Jun 2024
Clarify Pharma (AQSE:PSYC)
Historical Stock Chart
From Jun 2023 to Jun 2024